Tag: Samsung Bioepis

Samsung Bioepis Expands in China

C-Bridge Capital forms new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-gen...

Samsung Cancer Drug Approved by FDA

The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers. Ontruzant, which will be marketed in the US by Me...

Biogen increases its investment in Samsung BioLogics

biogen
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis, a joint venture established in 2012 by Samsung BioLogics and Biogen.

Biogen and Samsung Bioepis launch HUMIRA biosimilar in Europe

biosimilars
Biogen (USA) and Samsung Bioepis (South Korea) announced the European launch of IMRALDI (adalimumab), a biosimilar referencing HUMIRA. Starting today, IMRALDI will begin launching in major markets acr...

Biogen expands its ownership in Samsung Bioepis

biogen
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics and Biogen.

AbbVie reached a resolution in intellectual property-related dispute

abbvie
AbbVie announced it reached a global resolution for all intellectual property-related litigation with the two companies regarding its biosimilar Imraldi (adalimumab).

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

biosimilars
Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Samsung Bioepis received EU approval for its Herceptin biosimilar

samsung
Samsung Bioepis announced the European Commission’s marketing authorization of ONTRUZANT, a biosimilar referencing Herceptin (trastuzumab)

Samsung Bioepis and Takeda will jointly develop new drugs

samsung
Samsung Bioepis Co., Ltd. announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company